Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label study evaluating the effect of peginterferon alfa-2a (40KD) (PEGASYS) or adefovir dipivoxil (ADV) on HBeAg seroconversion in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B

Next Previous
X
Search
Trial Profile

A randomized, open-label study evaluating the effect of peginterferon alfa-2a (40KD) (PEGASYS) or adefovir dipivoxil (ADV) on HBeAg seroconversion in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Adefovir dipivoxil
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche; Shanghai Roche Pharmaceuticals

    • Most Recent Events

    • 06 Apr 2020 According to an Assembly Biosciences media release, results of a retrospective analysis of patients from two Phase IV clinical trials (NCT00962533 and ISRCTN79659320) has been published in Hepatology, the journal of the American Association for the Study of Liver Diseases (AASLD).
    • 06 Apr 2020 Results of a retrospective analysis of patients from two Phase IV clinical trials (NCT00962533 and ISRCTN79659320), presented in an Assembly Biosciences media release.
    • 08 Dec 2009 Actual end date (1 Jun 2008) added as reported by ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top